Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Weight gain and antidepressants.

¹Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA.

The Journal of Clinical Psychiatry

|August 5, 2000

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Spine surgery and complication in familial dysautonomia: a case report.

Frontiers in surgery·2025

Same author

Promoting resilience in healthcare workers during the COVID-19 pandemic with a brief online intervention.

Journal of psychiatric research·2021

Same author

A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.

Molecular psychiatry·2019

Same author

Salience network coupling is linked to both tobacco smoking and symptoms of attention deficit hyperactivity disorder (ADHD).

Drug and alcohol dependence·2017

Same author

Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1].

Journal of affective disorders·2017

Same author

Revisiting the role of the insula and smoking cue-reactivity in relapse: A replication and extension of neuroimaging findings.

Drug and alcohol dependence·2017

Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026

Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026

Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026

Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026

Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026

Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026

See all related articles

Antidepressant weight gain can be a side effect, not just a symptom. Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) may pose a higher risk than selective serotonin reuptake inhibitors (SSRIs).

Area of Science:

Pharmacology
Psychiatry
Clinical Medicine

Background:

Weight gain during antidepressant therapy can be complex, potentially indicating treatment improvement or a persistent symptom.
Significant or persistent weight gain is often an antidepressant side effect, contributing to treatment noncompliance.

Purpose of the Study:

To review and compare the relative risk of weight gain associated with various classes of antidepressant medications.
To inform clinical practice regarding antidepressant-induced weight gain and its management.

Main Methods:

Literature review of studies examining antidepressant-associated weight gain.
Comparative analysis of weight gain risks across different antidepressant categories.

Main Results:

Related Experiment Videos

Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) appear to have a higher risk of weight gain compared to selective serotonin reuptake inhibitors (SSRIs).
Mirtazapine's risk may fall between SSRIs and TCAs; paroxetine might increase weight gain risk more than other SSRIs long-term.
Bupropion and nefazodone may have a lower long-term weight gain risk than SSRIs, though further research is needed.

Conclusions:

Antidepressant-induced weight gain is a significant clinical concern impacting adherence.
Understanding the differential risks of weight gain among antidepressants (e.g., TCAs, MAOIs, SSRIs, mirtazapine, bupropion) is crucial for patient care.